669002-51-1

Basic information

• Product Name: Benzeneethanamine, 4-(1-piperidinylmethyl)-
• CAS NO: 669002-51-1
• Molecular Formula: C14H22N2
• Molecular Weight: 218.342
• Mol File: 669002-51-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzeneethanamine, 4-(1-piperidinylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneethanamine, 4-(1-piperidinylmethyl)-(669002-51-1)
• EPA Substance Registry System: Benzeneethanamine, 4-(1-piperidinylmethyl)-(669002-51-1)

Safety Data

• Hazardous Substances Data: 669002-51-1(Hazardous Substances Data)

Upstream product

• 935858-11-0 [2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 110-89-4 piperidine 
• 132690-91-6 4-[2-(tert-butyloxycarbonylamino)ethyl]benzoic acid 
• 929017-44-7 {2-[4-(piperidine-1-carbonyl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 

Downstream Products

• 929017-55-0 4-oxo-5-[2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine-2-carboxylic acid ethyl ester 
• 929017-88-9 7-(4-fluoro-benzoyl)-2-[2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one 
• 929017-80-1 1-oxo-2-[2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-1,2,3,4-tetrahydro-pyrrolo[1,2-a]pyrazine-7-carboxylic acid 
• 929017-97-0 7-bromo-2-[2-(4-piperidin-1-ylmethyl-phenyl)-ethyl]-3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one 
• 928674-95-7 tert-butyl 4-[4-(piperidin-1-ylmethyl)phenethyl]-3-oxopiperazine-1-carboxylate 

Relevant articles and documents

Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists

The synthesis and biological testing of novel classes of potent melanin-concentrating hormone (MCH-R1) antagonists based on pyrazolopiperazinone and pyrrolopiperazinone scaffolds are described.

New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture

The present invention relates to carboxamide compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1, R2, R3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.